Formoterol fumarate is a long-acting β 2 -agonist that is an effective bronchodilator for the maintenance management of patients with chronic obstructive pulmonary disease. The safety profile of the newly developed nebulized formoterol was evaluated over a twelve-month period in an open-label, active-control study. After completing a twelve-week double-blind doubledummy period, 569 subjects with chronic obstructive pulmonary disease entered an open-label extension study and received twice-daily 20 µg formoterol fumarate inhalation solution for nebulization (FFIS) or 12 µg formoterol fumarate dry powder inhalation (FA) for 52 weeks. Most of the FFIS-treated subjects (86%) completed at least six months of open-label treatment with over 90% compliance, comparable to the FA group (88%). Results of safety monitoring for adverse events, laboratory values, and cardiac changes were similar between treatment groups. Three hundred forty (73%) of FFIS-treated subjects and 83 (78%) of FA-treated subjects experienced an adverse event over the course of the study, the majority of which were mild to moderate and considered unrelated to treatment. COPD exacerbation occurred in 15.8% of FFIS-treated and 17.9% of FA-treated subjects. Deaths, serious adverse events, and discontinuations for adverse events occurred in 1.3, 16.2, and 5.4% of the nebulized group versus 1.9, 17.9, and 7.5% of the inhaled group, respectively. There were no clinically important changes from baseline in laboratory tests, including serum potassium and glucose, or vital signs and no treatment-related increases in cardiac arrhythmias, heart rate, or QTc prolongation. We conclude that nebulized formoterol fumarate twice daily is well tolerated over long-term treatment in moderate-to-severe COPD subjects and has a similar safety profile to the DPI formulation.
Introduction
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend a step-wise approach for COPD management, with regular bronchodilator treatment as a key part of the management strategy for patients with moderate-to-severe disease [GOLD, 2006] . Maintenance treatment with long-acting β 2 -agonists (LABA) is more effective and convenient than short-acting β 2 -agonists (SABA) [GOLD, 2006] , is well tolerated, and provides significant improvement in lung function, improvement in health status, and a reduction in exacerbations in subjects with COPD [GOLD, 2006; Appleton et al. 2006; Sovani et al. 2004 ]. However, recent asthma literature has raised concerns regarding the long-term use et al. Salpeter et al. 2006; Cazzola et al. 2005; Mann et al. 2003 ]. In addition, COPD patients frequently suffer from complex comorbidities affecting more than just the lungs [Fabbri et al. 2008 ] and requiring long-term vigilance and management.
Formoterol fumarate is a LABA that has been widely studied and marketed globally. At a range of doses, formoterol improves airflow obstruction in subjects with COPD [Campbell et al. 2005; Aalbers et al. 2002; Cheer and Scott, 2002; Rossi et al. 2002; Dahl et al. 2001] . Formoterol dry powder inhaler (DPI) provides more effective bronchodilation than theophylline [Rossi et al. 2002] or ipratropium bromide [Dahl et al. 2001 ].
The long-term tolerability of formoterol DPI has been demonstrated in a large post-marketing surveillance study [Wilton and Shakir, 2002] and a twelve-month double-blind, placebo-controlled study [Rossi et al. 2002] .
A new formulation of racemic formoterol fumarate has been developed as an inhalation solution for nebulization. Pharmacodynamic and pharmacokinetic studies established that a 20 µg dose of nebulized formoterol fumarate is comparable to the marketed 12 µg dose of formoterol fumarate DPI (Gross et al. 2008a; Carpenter et al. 2008) . In a twelve-week trial, formoterol fumarate inhalation solution administered twice daily has been shown to provide comparable efficacy and safety to formoterol fumarate DPI [Gross et al. 2008b] . Although a large body of clinical evidence regarding the safety of formoterol delivered by DPI is available [Berger and Nadel, 2008] , including the large controlled twelve-month trial [Rossi et al. 2002] , no data were available to confirm the long-term safety of the nebulized product, a matter of considerable importance when treatments are used daily as maintenance therapy and when comorbid conditions require complex concomitant medication regimens. Therefore, we conducted a twelve-month extension study to examine the safety of nebulized formoterol and compare it to that of formoterol DPI in the long-term treatment of COPD.
Methods

Study subjects
The study was an open-label safety extension to a twelve-week double-blind, double-dummy study that examined the safety and efficacy of formoterol fumarate inhalation solution for nebulization (FFIS) compared to formoterol fumarate DPI (FA) and placebo conducted in 569 adult male and female subjects at 66 study centers across the United States. Subjects were ≥ 40 years old, current or former smokers (>10 pack years), and had a diagnosis of COPD. Subjects enrolled into the preceding double-blind phase of the study had a post-bronchodilator FEV 1 ≥30% and < 70% of predicted normal and an FEV 1 /FVC ratio < 70% at screening as well as a pre-dose FEV 1 within 15% of the screening pre-bronchodilator FEV 1 and <70% of predicted at randomization. Subjects were excluded if they had a diagnosis of asthma, had evidence of other significant disease, had experienced an exacerbation of COPD or a respiratory tract infection within 30 days, were pregnant or of child-bearing potential not using adequate contraception, had required oral prednisone >10 mg every day or >20 mg every other day or long-term oxygen therapy within 30 days of screening, were taking nonselective β-blockers or monoamine oxidase inhibitors, were hypersensitive to β 2 -agonists, or had received radiation or chemotherapy within the last 12 months. Exclusion criteria also included unstable cardiac condition, myocardial infarction within the previous six months, and an electrocardiogram (ECG) with a QTc >0.46 s.
Study design
Subjects enrolled in the open-label extension study were treated either with twice-daily formoterol fumarate (Perforomist™ inhalation solution, FFIS, Dey, LP, Napa, CA) 20 µg delivered via nebulizer (Pari LC ® Plus jet nebulizer and Pari PRONEB ® compressor) or formoterol fumarate 12 µg delivered by DPI (Foradil ® Aerolizer ® , FA, Novartis Pharmaceuticals, East Hanover, NJ). Subjects randomly assigned to receive FFIS and placebo during the double-blind phase continued on FFIS treatment during the open-label extension. Subjects randomly assigned to receive FA during the double-blind phase were randomized to either FFIS or FA (1:1) for treatment during the open-label extension. The study was approved by institutional review boards and conducted in accordance with the Declaration of Helsinki. Each subject provided written informed consent and was able to discontinue participation at any time.
Use of long-acting β-agonists other than study medication was prohibited, but other medications for COPD were permitted, including shortacting β-agonists for symptomatic relief, inhaled corticosteroids, and tiotropium.
Study methods
Upon completion of the double-blind, doubledummy phase of the study, subjects were entered into the open-label phase. At the open-label baseline visit, spirometry, clinical laboratory tests, vital signs, and twelve-lead ECGs were obtained. A study diary was dispensed to record daily administration of study medication, changes in concomitant medications, adverse events, physician's office or emergency room visits, and hospitalizations. Compliance was assessed by accounting for used and unused capsules and vials at each visit. Noncompliance with treatment was defined as <80% or >120% of twice-daily administration and could result in discontinuation from the study.
At Week 2, a telephone contact was made to collect and discuss study medication use, concomitant medication use, smoking status, adverse events, and the study diary. At each subsequent visit (Weeks 10, 20, 30, 40, and 52 or Early Termination), vital signs, concomitant medication use and adverse events were collected and the study diary was reviewed. Laboratory tests, ECGs, and physical examinations were repeated at Week 10 and Week 52 or the Early Termination visit. Clinically significant abnormal changes from baseline in laboratory values or physical examination were recorded as adverse events. A COPD exacerbation was considered an adverse event in this study; it was defined as a change in symptoms that required (1) an increase in use or addition of corticosteroids, antibiotics, or oxygen for three or more days and/or (2) hospitalization or extension of hospitalization.
Statistical methods
Descriptive statistics were provided for the safety population, which consisted of all patients who took at least 1 dose of study medication. A sample size of 690 patients was selected for the doubleblind study so that long-term safety data would be available for 300 patients at six months of exposure and 100 patients at twelve months of exposure to FFIS in the open-label extension. QT intervals were corrected for heart rate by both Bazett's and Fridericia's correction. Treatmentemergent adverse events (TEAEs) were defined as events that began after the initiation of study medication (Day 1) or increased in severity or frequency, and they were coded using the Medical Dictionary for Regulatory Affairs (MedDRA) version 7.0.
Results
Study subjects
Of the 694 subjects enrolled in the twelve-week double-blind period of the study, a total of 569 subjects (81.9%) entered the open-label extension, 463 in the FFIS group and 106 in the FA group. Similar percentages of subjects in the FFIS (60.7%) and FA (64.2%) groups completed the study. Of the 448 FFIS subjects with available exposure data, 387 subjects (86.4%) completed at least 180 days of treatment, and the median and mean duration of exposure was 359 and 314 ± 104 days, respectively; exposure results were similar in the FA group. Table 1 describes the characteristics of the study population at baseline of the open-label extension phase. Overall, the population averaged 64.3 years of age (range 40-89) and about half were males and current smokers. Most were Caucasian (87.5%). Mean pre-bronchodilator values for FEV 1 and FVC were 1.34 L and 2.49 L, respectively. The characteristics were comparable between treatment groups and as expected in this stable moderate-to-severe COPD population.
Most of the subjects (72.4%) used medications for COPD in addition to the study medication, including albuterol (57.8%), prednisone (20.7%), fluticasone (22.0%), furosemide (11.4%), ipratropium bromide (9.0%), and theophylline (1.2%). Use of these medications and medications of other classes was similar between treatment groups. Tiotropium was used by three patients in the FFIS group (0.6%). Compliance with twice-daily study medication administration was at least 90% in both treatment groups up through Week 40, and dropped to approximately 86% by the final visit. 
Adverse events
Overall, 74.3% of subjects reported at least one adverse event. Adverse events most commonly reported are listed in Table 2 ; the incidence of adverse events was similar between the two treatment groups. COPD exacerbations were the most common followed by upper respiratory tract infections. There were no meaningful differences within gender, age, or ethnic subgroups in the incidence of adverse events, although slightly more older subjects and females in the FFIS group reported AEs than younger or male subjects. The majority of adverse events were rated as mild or moderate in severity. Adverse events that were considered by the investigator to be related to treatment were reported by 11.4% of the FFIS group and 8.5% of the FA group, but no individual event was considered related to study treatment in 2% or more patients in either group. Adverse events commonly associated with β-agonist treatment, such as tremor or palpitations, were reported in <1% of subjects. Similar rates of discontinuation due to adverse events occurred in the two treatment groups (Table 3) , the most common being for COPD exacerbations (1.1 and 1.9% in the FFIS and FA groups, respectively). Serious adverse events (SAEs) were reported at similar rates in the FFIS and FA populations (Table 3) . COPD exacerbation was the only SAE reported in 2% or more subjects in the FFIS (2.6%) and FA (6.6%) groups. Six subjects (1.3%) in the FFIS group and two subjects (1.9%) in the FA group died ( Table 3) . Causes of death for FFIS-treated subjects included cardiac arrest, COPD exacerbation, myocardial infarction, coronary artery disease, congestive heart failure, and nonsmall cell lung cancer and for FA-treated subjects multi-organ failure and cerebral hemorrhage.
Clinical laboratory tests
Most subjects had normal hematology and chemistry values at baseline and no change from normal to the final visit. However, more than 5% of subjects experienced changes in serum creatinine, uric acid, glucose, sodium, WBC, and neutrophils from normal to high and of lymphocyte percentage from normal to low, which were similar between treatment groups. There was little change in mean values from baseline to Week 10 or Week 52 for any hematology, chemistry, or urinalysis parameter in either group. Mean changes from baseline to Week 52 for serum glucose and potassium were 0.4 mg/dL and 0.0 mEq/L, respectively, in the FFIS group. The incidence of potentially clinically significant (PCS) laboratory values or potentially clinically significant changes (PCSC) from baseline was low in both groups, and few patients in either group had a laboratory value that met criteria for both PCS and PCSC.
12-lead electrocardiogram ECG measurements at baseline, Week 10 and
Week 52 or early termination are presented in Table 4 along with the post-dose change from screening at Week 52. At each time point, mean changes from baseline in heart rate and QT interval were small and comparable between treatment groups. Most subjects in both treatment groups had a maximum change from baseline in corrected QT intervals (QTcB or QTcF) that was <30 ms (Table 4) , and few subjects had a maximum change from baseline ≥60 ms.
Vital signs
The FFIS and FA groups had small and comparable mean changes from baseline in all vital signs, including systolic blood pressure, diastolic blood pressure, and heart rate at all time points. Very few subjects (≤1.1%) at any time point met the criteria for clinically significant results for blood pressure. Heart rate was clinically significantly high in 1.0% of the FFIS group and 4.3% of the FA group and clinically significantly low in 0.8% of the FFIS group and 1.1% of the FA group at the end of treatment.
Discussion
The results of this open-label active-controlled study suggest FFIS was well tolerated when used for up to one year as maintenance therapy in subjects with moderate-to-severe COPD. The rates of death, adverse events, COPD exacerbations, serious adverse events, and discontinuations for adverse events were low and similar to those in the active control group. The reported adverse events were typical of this population and of long-term studies, and generally not considered to be related to study medication. Clinically significant laboratory abnormalities were rare and ECG measurements demonstrated no clinically meaningful changes over the treatment period with few differences between groups. Subjects (≤1.1%) with QTc prolongation at a clinically meaningful level were rare at any time during the year's treatment duration. The long-term safety results for FFIS, together with the efficacy and safety results of a double-blind, placebo-and activecontrolled twelve-week study [Gross et al. 2008b; Nelson et al. 2007 ], confirm comparable safety and efficacy of formoterol fumarate delivered by DPI and nebulization.
Subjects enrolled in this study experienced a low incidence of adverse experiences or morbidity while on nebulized twice-daily formoterol fumarate. Furthermore, they demonstrated a high rate of compliance and retention in the study, similar to the dry powder inhaler. Approximately 86% of subjects received at least 180 days of treatment, and over 60% of subjects completed the study. Over 85% were compliant with their twice-daily dosing regimen upon assessment at each study visit. These results may be suggestive of satisfaction with nebulization; however, this needs to be confirmed with patient questionnaire data.
Nebulization is an advantageous delivery system for certain populations because unlike other inhaled devices [van Beerendonk et al. 1998; Thompson et al. 1994] , it requires little coordination or cooperation, is not dependent on inspiratory drive, and is less likely to introduce dosing errors. Other studies have demonstrated the benefits of nebulization [O'Driscoll and Bernstein, 2006; Yohannes and Hardy, 2003; Barta et al. 2002] , and some patients consider nebulization better than inhalers at controlling symptoms, improving well-being, and increasing independence [Barta et al. 2002] . A systematic review to assist in the development of evidencebased guidelines for device selection concluded that all devices could be equally efficacious and that selection criteria should include setting, patient age and ability, convenience, and preference [Dolovich et al. 2005 ]. However, until recently the only bronchodilators available in nebulized form for COPD were SABAs and anticholinergic drugs that require four times daily administration. A nebulized version of formoterol fumarate provides additional convenience of twice-daily dosing for COPD patients.
Our results confirm previously published safety results from studies of long-term formoterol treatment for COPD. Rossi et al. [2002] evaluated FA 12 and 24 µg twice-daily treatment in a similar but somewhat less severe population for twelve months. In their placebo-controlled study, subjects receiving FA 12 µg twice daily experienced rates for deaths (1.4%), serious adverse events (12.3%), and discontinuations due to adverse events (5.7%) similar to those we report here for the FFIS and FA groups in our open-label study. In two double-blind, placebo-controlled studies [Calvarley et al. 2003; Szafranski et al. 2003 ] of 9 µg twice daily formoterol dry powder delivered via a Turbuhaler ® for twelve months to subjects with moderate-to-severe COPD, rates for COPD exacerbations, death, serious adverse events, and discontinuations for adverse events were also comparable but somewhat higher than we report. Our results are also similar to those of previous one-year studies of inhaled formoterol treatment for COPD in that they reported no treatment-related increases in ECG or laboratory abnormalities [Szafranski et al. 2003; Rossi et al. 2002] . A post-marketing surveillance study of FA use in 5777 patients in England similarly reported that formoterol fumarate treatment, principally for asthma and COPD, was well tolerated and was continued for longer than twelve months in the majority of patients [Wilton and Shakir, 2002] . In a prospective study, the introduction of formoterol to short-acting bronchodilators in hospital treatment protocols reduced adverse events in asthma and COPD patients compared with pre-formoterol time periods [Colice et al. 2005 ].
Double-blind, placebo-controlled studies with a shorter duration of formoterol treatment for COPD also confirm the tolerability of inhaled formoterol, including the new formulation for nebulization. Gross et al. [2008b] reported twelve weeks of FFIS treatment in moderate-to-severe COPD subjects was well tolerated; rates of adverse experiences and ECG changes were low and similar between the FFIS and FA groups. Tashkin et al. [2008] reported that FFIS was well tolerated when combined with tiotropium maintenance therapy for twelve weeks. Other controlled studies of formoterol dry powder inhaler treatment for COPD of 12 to 26-week duration reported similar safety results [Campbell et al. 2005; Aalbers et al. 2002; Dahl et al. 2001 ].
We observed one respiratory-related death in the current one-year study. Concerns regarding the possible contribution of LABA treatment to serious exacerbations or respiratory-related deaths [Cazzola and Matera 2007; Nelson et al. 2006; Salpeter et al. 2006; Cazzola et al. 2005; Mann et al. 2003 ] were raised following the report of statistically significant differences in respiratory-related and asthma-related deaths between salmeterol and placebo-treated subjects in a large asthma trial [Nelson et al. 2006 ], and a meta-analysis of controlled trials of LABA treatment for COPD concluded that LABA treatment was associated with an increased risk of respiratory-related death [Salpeter et al. 2006] . A more recent large three-year survival study in COPD patients demonstrated that salmeterol treatment reduced exacerbations and did not increase the risk of all-cause mortality or COPDrelated deaths compared with placebo treatment [Calverley et al. 2007 ]. Although our study was not placebo-controlled nor was it as large, we can confirm that the rate of COPD exacerbation and respiratory-related death was not high in this moderate-to-severe COPD population treated with a LABA.
Overall, eight deaths occurred during the one-year treatment period. Four in the FFIS group were cardiac related; none were deemed related to study medication. ECG measurements throughout the study did not reveal any treatment-related increase in cardiac arrhythmias, heart rate, or QTc prolongation. Adverse events such as tremor or palpitations, considered expected for β-agonists, were observed in <1% of the subjects over the course of the year. Furthermore, the twelve-week placebocontrolled study in moderate-to-severe COPD demonstrated no cardiovascular effects of FFIS treatment using standard ECG and Holter monitoring [Nelson et al. 2007] , and other controlled studies of low-dose LABA treatment for COPD have reached the same conclusion [Campbell et al. 2007; Ogale et al. 2006; Ferguson et al. 2003 ]. Therefore, it is difficult to determine if the observed deaths were related to treatment or the underlying cardiovascular comorbidities often associated with COPD [Sin et al. 2006; Rutten et al. 2005; Shih et al. 1988 ].
The current study had several limitations. There was no placebo control; the active FA control gave some indication the safety of FFIS was comparable to a LABA inhaler, as does comparison with data from previously published placebo-controlled studies. Also, the population studied was relatively free of other severe chronic and underlying significant cardiac conditions and excluded COPD patients with a recent myocardial infarction or prolonged QTc interval, which may compromise the generalizability of the study to all COPD patients.
Conclusions
We conclude that the long-term use of formoterol fumarate inhalation solution delivered via a nebulizer is well tolerated in subjects with moderate-to-severe COPD and thus may provide an alternative to LABAs delivered via other delivery systems.
